Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center, 1993-2001 by Ammann, Roland et al.
Support Care Cancer (2004) 12:826–832
DOI 10.1007/s00520-004-0660-z O R I G I NA L ART I C L E
Roland A. Ammann
Christoph Aebi
Andreas Hirt
Annette Ridolfi Lthy
Fever in neutropenia in children
and adolescents: Evolution over time
of main characteristics in a single center,
1993–2001
Received: 19 January 2004
Accepted: 1 June 2004
Published online: 8 July 2004
 Springer-Verlag 2004
The results of this study have been pre-
sented in part at the 35th Annual Congress
of the International Society of Paediatric
Oncology (SIOP) in October 2003 in Cairo.
R. A. Ammann ()) · C. Aebi · A. Hirt ·
A. Ridolfi Lthy
Division of Pediatric Hematology
and Oncology,
University Children’s Hospital,
University of Bern,
Bern, Switzerland
e-mail: roland.ammann@insel.ch
Tel.: +41-31-6329372
Fax: +41-31-6329507
C. Aebi
Institute for Infectious Diseases,
University of Bern,
Bern, Switzerland
Abstract Goals of work: To assess
the evolution over time of main
characteristics of episodes of fever in
severe chemotherapy-induced neu-
tropenia (FN) in children and ado-
lescents with cancer treated for FN
following nonmyeloablative chemo-
therapy, to compare the results with
the experiences of other centers, and
to assess the impact of the changes
found on management of FN and on
risk prediction rules. Patients and
methods: Retrospective cohort study
of all children and adolescents up to
18 years presenting with FN in a
single pediatric oncology unit be-
tween 1993 and 2001. Main results:
In 132 patients, 364 episodes of FN
were reported. The relative incidence
of FN increased significantly over
time in patients with precursor B-cell
acute lymphoblastic leukemia (PBC-
ALL), reflecting the increased inten-
sity of chemotherapy. At presentation
with FN, the proportions of patients
(1) with PBC-ALL versus other ma-
lignancies, (2) with other malignan-
cies being in complete remission, (3)
with a central venous catheter, and
(4) with shaking chills all signifi-
cantly increased over time (overall
proportions, 64%, 60%, 50%, and
5%, respectively; p <0.001 for all).
In 337 (93%) episodes, ceftriaxone
plus amikacin was used as empirical
broad spectrum antimicrobial thera-
py. Conclusions: This study demon-
strates that some characteristics of
FN, though not necessarily its man-
agement, change over time, implying
regular update of risk prediction
rules. In contrast to other centers, the
first-line antimicrobial therapy did
not need modification because of
changing resistance patterns.
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Introduction
Fever in severe chemotherapy-induced neutropenia (FN)
is the most frequent potentially life-threatening compli-
cation in adult and pediatric oncology. Compared to
adults, children with FN are less likely to have a clini-
cally apparent site of infection, but the overall proportion
of detectable bacteremia is similar, ranging from 10% to
30% [2, 14]. The incidence of significant bacterial in-
fections, including bacteremia, positive urine culture,
pneumonia, or unexpected death from infection [16] is
higher, ranging from 20% to 55% [2, 16]. Despite the fact
that only a minority of episodes of FN are caused by
detectable bacterial infections, immediate empirical treat-
ment with broad spectrum antibiotics is mandatory in all
episodes of FN in children. Without such therapy, usually
administered in an inpatient setting, case-fatality rates up
to 80% in the case of gram-negative infections would be
expected [2].
Recently, rules for the prediction of episodes of FN at
low risk of complications have been established not only
in adult oncology [17] but also in retrospective [1, 4, 8,
14] and prospective [11, 16, 18, 19, 22, 23] pediatric
studies, though there is no multinationally accepted risk
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prediction rule in pediatric oncology. The purpose of
these risk prediction rules is to allow for outpatient man-
agement and oral antimicrobial therapy in selected low-
risk episodes of FN.
Information on possible changes over time of charac-
teristics in pediatric FN are contradictory [6, 15, 21, 24,
28]. Such changes can require adaptation of the man-
agement of FN itself, e.g., the choice of empirical broad-
spectrum antimicrobial therapy and of rules predicting
low-risk episodes of FN [12]. The primary purpose of this
study was to assess the evolution over time of main char-
acteristics of epidemiology, presenting signs and symp-
toms, management, and outcome of episodes of FN in a
single tertiary care center of pediatric oncology. Second-
ary purposes were to compare this evolution with results
published by other centers and to assess the potential im-
plications on management of FN itself and on risk-pre-
diction rules in pediatric FN.
Patients and methods
Study design
A retrospective, single-site, cohort study was conducted at the
Division of Pediatric Hematology and Oncology, University Chil-
dren’s Hospital, University of Bern, Bern, Switzerland. Information
on all children and adolescents diagnosed with a neoplasm between
January 1, 1993 and December 31, 2001, and aged up to 17 years at
diagnosis was extracted from an electronic database. Charts were
screened for episodes of FN occurring within the same time interval
and up to the age of 18 years.
Patients/episodes
An episode of FN was defined as an axillary temperature 38.5C
persisting 2 h or as a single temperature measurement of 39.0C
in a child with severe neutropenia, i.e., an absolute neutrophil count
(ANC) 0.5109/l or an ANC 1.0109/l and supposed to decline
[2]. Repeated episodes per patient were allowed. Episodes of FN
due to bone marrow involvement by the disease itself, e.g., at the
time of diagnosis of leukemia, and episodes following myeloabla-
tive therapy were excluded. Information on characteristics at pre-
sentation with FN and on its management and outcome were col-
lected. Bacteremia was defined as at least one positive blood cul-
ture bottle irrespective of the species detected, i.e., including co-
agulase-negative staphylococci (CoNS). Details of data collection
have been described elsewhere [4]. During the time period studied,
there was no antibiotic prophylaxis given [9], with the exception of
trimethoprim-sulfamethoxazole (5 mg/kg trimethoprim + 25 mg/kg
sulfamethoxazole per day, 3 days per week) as prophylaxis against
Pneumocystis jiroveci pneumonia. Most patients were treated ac-
cording to protocols of the Pediatric Oncology Group.
Statistical methods
The evolution of characteristics of FN over the time period studied
was assessed graphically and with the test for trend in ordered
Poisson rates for incidences, the Cochran-Armitage test for binary
variables, and the Jonckheere-Terpstra test for continuously mea-
sured variables, respectively [25]. Two-tailed exact tests were used
throughout. Because of the exploratory nature of the study [3], no
formal corrections for multiple testing were made, but only p values
<0.01 were considered significant. Repeated episodes per patient
were allowed without formally applying the corresponding statis-
tical techniques. Analyses concerning only the first episode of FN
per patient were performed wherever appropriate. Diagnosis of a
neoplasm and presentation with FN were restricted to the same
period of time. In order to correct for possible influences of this
fact, data concerning the years 1993 or 2001 were excluded from
analysis wherever appropriate in the epidemiological section. Be-
cause of the high proportion of episodes of FN in patients with
precursor B-cell acute lymphoblastic leukemia (PBC-ALL), com-
parisons between patients with PBC-ALL versus all other diagnoses
were performed where appropriate. The StatXact 5.0.3 (CYTEL
Software Corp., Cambridge, MA, USA) software was used for
exact tests.
Results
Epidemiology
Between January 1, 1993, and December 31, 2001, 385
patients were diagnosed with a neoplasm. (See Fig. 1 for
the spectrum of diagnoses.) Of these, 290 (75%) were
treated with chemotherapy. Both the incidences of pa-
tients diagnosed with a neoplasm and of patients treated
with chemotherapy were decreasing over time (Table 1).
The incidence of patients diagnosed with PBC-ALL re-
mained constant, while the number of new patients with
other malignancies decreased. In 132 (46%) of the 290
patients treated with nonmyeloablative chemotherapy,
364 episodes of FN were reported. The median number of
episodes of FN per patient was two. The proportion of
patients with chemotherapy and at least one episode of
Fig. 1 Diagnoses of new patients treated in our center between
1993 and 2001. CNS tumors of the central nervous system, PBC-
ALL precursor B-cell acute lymphoblastic leukemia, NHL non-
Hodgkin lymphoma, LCH Langerhans cell histiocytosis, AML acute
myeloid leukemia. ALL other acute lymphoblastic leukemia other
than PBC-ALL
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FN remained stable over time, as was the absolute inci-
dence of FN. The relative incidence, i.e., the number of
episodes of FN per patient treated with chemotherapy,
however, increased significantly in patients with PBC-
ALL but not in patients with other malignancies.
Characteristics at presentation with FN
Episodes of FN in patients with PBC-ALL increased
significantly over time, while episodes in patients with
other malignancies decreased (Table 2). This evolution
was identical in patients with and without relapse (data
not shown). In patients with malignancies other than
PBC-ALL, the proportion of patients being in complete
remission at presentation with FN increased over time.
The proportions of patients presenting with FN (1) after a
low intensity chemotherapy, i.e., comparable to continu-
ation therapy in PBC-ALL; (2) with a central venous
catheter; and (3) with shaking chills, all increased sig-
nificantly over time. The median leukocyte count de-
creased significantly over time. The ANC at presentation
remained stable. It was determined in only 174 (48%) of
the episodes, since no differentiation was performed with
Table 1 Epidemiology. PBC-
ALL precursor B-cell acute
lymphoblastic leukemia, FN
episode of fever in severe che-
motherapy-induced neutrope-
nia, n.s. not significant, i.e.,
p 0.01
Characteristic Sample size Statistic p value
Patients diagnosed with neoplasm 385 3.00 a 0.003
Patients treated with chemotherapy 290 3.14 a 0.002
PBC-ALL 84 1.01 a n.s.
Other diagnoses 206 3.08 a 0.002
Absolute incidence of FNb 335 0.38 a n.s.
Patients with chemotherapy and at least one FN 132 0.87 c n.s.
Number of FN per patient treated with chemotherapyd 264 3.36 a <0.001
In patients with PBC-ALLd 74 5.06 a <0.001
In patients with other diagnosesd 190 0.23 a n.s.
a Standardized test statistic of the exact test for trend in ordered Poisson rates
b Data from 1993 excluded from analysis: 29 episodes
c Standardized test statistic of the exact Cochrane-Armitage test for trend in binary data
d Data from 2001 excluded from analysis: 26 patients, ten of them with PBC-ALL
Table 2 Characteristics at presentation with episode of fever in severe chemotherapy-induced neutropenia (FN). PBC-ALL precursor
B-cell acute lymphoblastic leukemia, G-CSF granulocyte colony-stimulating factor, n.s. not significant, i.e., p  0.01
Characteristic Sample size Overall median/% Statistic p value
Age at first FN (years) 132 6.6 0.21 a n.s.
Gender at first FN (female0 132 39% 0.60 b n.s.
Diagnosis of PBC-ALL, only first FN 132 32% 1.91 b n.s.
Diagnosis of PBC-ALL 364 34% 6.49 b <0.001
Time since diagnosis at first FN (months) 132 1.4 0.77 a n.s.
Complete remission 364 60% 4.43 b <0.001
PBC-ALL 123 80% 1.07 b n.s.
Other diagnoses 241 49% 3.77 b <0.001
Bone marrow free of malignancy 364 85% 2.11 b n.s.
Low intensity of chemotherapy c 364 26% 2.61 b 0.008
Prophylaxis with G-CSF 363 52% 2.40 b n.s.
Central venous catheter inserted 364 50% 6.35 b <0.001
Yet hospitalized before developing FN 364 15% 1.99 b
Shaking chills observed 362 6% 3.16 b 0.001
Maximum temperature within first 2 h (C) 359 39.1 1.71 a n.s.
General appearance nontoxic 304 26% 1.06 b n.s.
Shaking chills observed 362 6% 3.16 b 0.001
Severe oral mucositis requiring i.v. hydration 324 2% 1.42 b n.s.
Independent comorbidity requiring hospitalization 364 20% 1.50 b n.s.
Radiologically defined pneumonia 364 3% 1.98 b n.s.
Hemoglobin level (g/l) 362 88 0.92 a n.s.
Leukocyte count (109/l) 362 0.50 2.78 a 0.006
Absolute neutrophil count (109/l) 174 0.06 0.78 a n.s.
Platelet count (109/l) 356 18 0.74 a n.s.
Serum level of C-reactive protein (mg/l) 329 48 2.43 a n.s.
a Standardized test statistic of the exact Jonckheere-Terpstra test
b Standardized test statistic of the exact Cochrane-Armitage test for trend in binary data
c Low intensity chemotherapy: comparable to continuation therapy in Precursor B-cell acute lymphoblastic leukemia
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leukocyte counts 0.5109/l, implying by definition an
ANC 0.5109/l. The other items of history, physical ex-
amination, and auxiliary examination recorded at presen-
tation with FN did not change significantly over time.
Management
Patients were hospitalized in 361 (99.2%) episodes and
treated with intravenous broad spectrum antibiotics in 356
(97.8%) of 364 episodes. In 337 (93%) of the episodes,
the initial antimicrobial therapy was a combination of
ceftriaxone plus amikacin [10]. This proportion remained
stable (Table 3). The number of blood cultures performed
per episode increased significantly, as was the proportion
of episodes with at least one urine culture performed. The
maximum value of the C-reactive protein increased over
time. The median duration of hospitalization and of in-
travenous antimicrobial therapy, as well as the leukocyte
and absolute neutrophil count at discharge, all remained
stable over time. The proportion of patients discharged
from hospital with continuing intravenous antimicrobial
therapy in the outpatient setting, however, increased over
time (Fig. 2).
Outcome
Two of 132 (1.5%) patients died because of infection, one
in 1994, and one in 2001. There was a nonsignificant
tendency towards increasing proportions of episodes with
bacteremia in total, gram-negative bacteremia, bacteremia
by CoNS, and bacteremia detected during administration
of broad spectrum intravenous antimicrobial therapy (Ta-
ble 4). In 28 (88%) of the 32 episodes with positive blood
cultures taken during administration of broad spectrum
intravenous antimicrobial therapy, CoNS was detected.
Pseudomonas aeruginosa was detected twice in blood
cultures, i.e., in 0.5% of the episodes and once in urine.
Further details on the organisms causing bacteremia have
been published elsewhere [5]. There were 19 clinically
and/or microbiologically defined localized bacterial in-
fections (ten skin and soft tissue, four head/neck/mouth,
three phlebitis associated with peripheral venous catheter,
and one each superinfected seroma and CNS). Their pro-
portion remained stable over time. There were 21 micro-
biologically confirmed viral infections (eight influenza A,
four respiratory syncytial virus, three parainfluenza, three
herpes simplex virus 1, and one each mumps, enterovirus,
and cytomegalovirus). Their proportion increased signifi-
cantly during the study period. There was one case of
suspected pulmonary aspergillosis.
Discussion
The evolution of the epidemiology of FN in a single
center must be interpreted on the background of the
evolution of the population treated with chemotherapy
and thus being at risk to develop FN. The decrease over
time of the absolute incidence of FN in patients with
diagnoses other than PBC-ALL, with a constant relative
Table 3 Management of Episode of fever in severe chemotherapy-induced neutropenia (FN). n.s. not significant, i.e., p 0.01
Characteristic Sample size Overall median / % Statistic p value
Number of blood cultures performed per FN 364 4 6.02 a <0.001
Episodes with at least one urine culture performed 364 59% 3.02 b 0.002
Highest serum level of C-reactive protein (mg/l) 358 87 4.51 c <0.001
Ceftriaxone plus amikacin as first-line therapy 364 93% 0.79 b n.s.
Duration of i.v. antimicrobial therapy (days) 363 5 0.95 c n.s.
Duration of hospitalization (days) 364 5 1.32 c n.s.
Leukocyte count at discharge (109/l) 320 2.00 0.51 c n.s.
Absolute neutrophil count at discharge (109/l) 261 0.77 0.29 c n.s.
Continued i.v. antimicrobial therapy at discharge 355 18% 3.08 b 0.002
a Standardized test statistic of the exact test for trend in ordered Poisson rates
b Standardized test statistic of the exact Cochrane-Armitage test for trend in binary data
c Standardized test statistic of the exact Jonckheere-Terpstra test
Fig. 2 Antimicrobial therapy at discharge after episode of fever in
neutropenia (FN)
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incidence, reflects the decreasing number of these pa-
tients. This in turn is due to the fact that until 1996, pa-
tients from the other Swiss pediatric oncology centers
were referred to Bern as the single Swiss center per-
forming autologous bone marrow/peripheral blood stem
cell transplantation. The stem cell mobilization regimen
often led to FN. Episodes of FN caused by myeloablative
therapy itself were not included in the study.
The increase over time of the intensity of chemother-
apy applied [5, 6, 15] is reflected by (1) the increasing
relative incidence of FN in patients with PBC-ALL irre-
spective of relapse status; (2) the increasing proportion of
patients with other malignancies who had reached com-
plete remission when presenting with FN; and (3) the
decreasing leukocyte count at presentation. This is in line
with the increased relative incidence of FN reported by
others [15, 28]. The increased proportion of patients with
central venous catheters presenting with FN simply re-
flects the more liberal indication to implant such a device,
despite the well known risk of catheter-related infections
by both gram-positive and gram-negative bacteria [2, 15,
27]. In contrast to other studies reporting on earlier pe-
riods [28], the proportion of patients receiving prophy-
lactic G-CSF support did not increase significantly, be-
cause the indications for its use remained grossly un-
changed since 1993.
As to management of the episodes of FN, diagnostic
procedures like blood and urine cultures were performed
with increasing frequency. This contrasts with the stable
detection rate both of bacteremia and urinary tract in-
fection. The present principle to repeat a set of blood cul-
tures whenever the patient develops fever 38.5C and/or
shaking chills does not seem to be justified. The increas-
ing maximum CRP levels probably reflect as well more
frequent measurements (no data available). The increas-
ing proportion of microbiologically confirmed viral in-
fections reflects an increase in diagnostics as well (no
data available). Viral diagnostics was performed when
clinically indicated but with increasing frequency due to
the increasing availability of sensitive and specific diag-
nostic methods. The increasing proportion of patients dis-
charged from hospital with continuing intravenous anti-
microbial therapy in the ambulatory setting was made
possible by the development of pediatric home nursing.
All other important topics of management remained un-
changed. Despite the publication of two reports on small
controlled [20] or uncontrolled [6] studies, the question of
safety and efficacy of outpatient management and/or oral
antimicrobial therapy in children and adolescents with FN
at low risk for complications remained unresolved during
the study period [13, 26]. Apart from rare exceptions, all
patients were thus hospitalized and immediately treated
with empirical intravenous broad-spectrum antimicrobial
agents. The proportion of episodes of FN with bacteremia
detected and the relative preponderance of gram-posi-
tive over gram-negative bacteremia were comparable to
published results [2, 14, 27] and remained stable over
time. The vast majority of bacteremia detected during ad-
ministration of broad-spectrum intravenous antimicrobial
therapy were caused by CoNS, which usually are not to
life-threatening. Thanks to these facts and the low abso-
lute incidence of Pseudomonas aeruginosa infections
(incidence of bacteremia, 0.5%), there was no necessity to
change the combination of ceftriaxone and amikacin [10]
as empiric first-line antimicrobial therapy during the
whole study period of 9 years. This is in line with the
results from Gaslini’s Children Hospital, Genova, Italy
[15], and from the Alder Hey Children’s Hospital in
Liverpool, UK [21]. A multicenter surveillance study per-
formed in 1995 in Italy [27] detected no major problem of
antibiotic resistance either.
Our results contrast sharply, however, with the experi-
ences reported from Innsbruck, Austria [28], where gram-
negative bacteria increasingly resistant to the administered
first-line antibiotic regimen became more prevalent, ne-
cessitating modifications of the antimicrobial strategy ev-
ery 3 years between 1986 and 1995. Differences in the
chemotherapeutic and antimicrobial therapy applied and
microbiologic epidemiology may explain these contrasting
results. Antimicrobial prophylaxis [9] beyond P. jiroveci
pneumonia prophylaxis cannot explain this discrepancy,
since it was not used in either center.
In contrast to other studies, only nonsignificant ten-
dencies towards increasing proportions of episodes with
Table 4 Outcome. FN episode of fever in severe chemotherapy-induced neutropenia, n.s. not significant, i.e., p 0.01
Characteristic Sample size Overall proportion Statistic p value
Death due to infection 364 0.5% 0.00 a n.s.
Bacteremia in total 364 24% 1.91 a n.s.
Gram-negative bacteremia 364 8% 1.82 a n.s.
Bacteremia by coagulase-negative staphylococci 364 11% 2.18 a n.s.
Bacteremia during broad spectrum i.v. therapy 364 9% 2.02 a n.s.
Polymicrobial bacteremia 364 3% 1.79 a n.s.
Radiologically confirmed pneumonia 364 13% a n.s.
Localized bacterial infection 364 5% 0.25 a n.s.
Microbiologically confirmed urinary tract infection 364 1.4% 1.39 a n.s.
Microbiologically confirmed viral infection 364 6% 3.60 a <0.001
a Standardized test statistic of the exact Cochrane-Armitage test for trend in binary data
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